Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

25
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
25
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

589
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
589
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.4K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.4K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Stroke characteristics in giant cell arteritis and Takayasu arteritis: A multicenter retrospective cohort study of 108 patients.

Seminars in arthritis and rheumatism·2026
Same author

[Assessment of internship sites in Internal Medicine and Clinical Immunology, 7 years after the Residency Training Program Reform: Findings from a 2024 year-end survey in France].

La Revue de medecine interne·2025
Same author

Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial.

Arthritis research & therapy·2025
Same author

Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study.

Rheumatology (Oxford, England)·2025
Same author

Giant cell arteritis mimics with severe consequences: a long-term monocentric inception cohort.

Rheumatology (Oxford, England)·2025
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Related Experiment Video

Updated: Feb 20, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.6K

[Giant cell arteritis].

Eric Liozon1, Kim Ly

  • 1Service de médecine interne A, CHU Dupuytren, Limoges. eric.liozon@unilim.fr

La Revue Du Praticien
|June 6, 2008
PubMed
Summary
This summary is machine-generated.

Giant cell arteritis (GCA) is a common vasculitis in older adults, diagnosed via biopsy and supported by imaging. Early corticosteroid treatment is crucial to prevent vision loss, with long-term monitoring for vascular complications.

More Related Videos

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro
10:05

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

Published on: January 25, 2017

16.0K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.2K

Related Experiment Videos

Last Updated: Feb 20, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.6K
Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro
10:05

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

Published on: January 25, 2017

16.0K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

14.2K

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is the most common systemic vasculitis affecting medium and large vessels, primarily in individuals over 60.
  • Clinical presentations of GCA can be diverse and occasionally misleading, complicating timely diagnosis.

Purpose of the Study:

  • To provide a comprehensive overview of giant cell arteritis, covering diagnosis, treatment, and long-term management.
  • To emphasize the importance of early diagnosis and treatment to prevent severe complications like blindness.

Main Methods:

  • Diagnosis relies on clinical suspicion, elevated inflammatory markers (erythrocyte sedimentation rate, C-reactive protein), and confirmed by temporal artery biopsy.
  • Non-invasive imaging techniques including ultrasonography, CT, MRI, and PET scans aid in diagnosing aortitis and aortic arch syndrome associated with GCA.

Main Results:

  • Prompt initiation of corticosteroid therapy is essential to mitigate the risk of visual impairment, including monocular or binocular blindness.
  • While many patients achieve treatment freedom within 2-3 years, they remain at increased risk for late-onset vascular issues.

Conclusions:

  • GCA requires urgent treatment, primarily with corticosteroids, to prevent irreversible vision loss.
  • Long-term surveillance is critical for patients with GCA to monitor for and manage potential vascular complications such as ischemic heart disease and aortic aneurysms.